Brain Scientific Inc. (OTCQB: BRSF)

The QualityStocks Daily Newsletter would like to spotlight Brain Scientific Inc. (OTCQB: BRSF).

Brain Scientific Inc. (OTCQB: BRSF) is a commercial-stage health care company focused on developing innovative and proprietary medical devices and software. With a mission of modernizing brain diagnostics by employing cutting edge technologies to bridge the widening gap in access to quality care, the company offers two FDA-cleared products that provide next-generation solutions to the neurology market.

The company’s proprietary, clinical-grade neurological devices are supported by its intellectual property portfolio featuring patents in the United States, China and Europe.

Brain Scientific’s first commercialized devices, NeuroCap(TM) and NeuroEEG(TM), are designed to disrupt the current electroencephalogram (EEG) market by offering cost-effective and disposable substitutes to existing solutions, allowing medical professionals to collect diagnostic information quickly.

The company’s goal is to improve diagnostics by leveraging artificial intelligence and machine learning processes to analyze a database of brain readings as a method of detecting seizures and dementia. The company is also working to improve patients’ access to neurological care.

Headquartered in New York, Brain Scientific and its predecessor (and now wholly owned subsidiary, MemoryMD Inc.) was founded in 2015 and went public in 2018.

Brain Scientific’s first phase of development, from 2018 to 2019, saw the inception of portable, clinical-grade, easy-to-use neurological devices. The second phase, currently ongoing, aims to create cloud-based, secure infrastructure to transmit patient data between patients and their neurologists. The company’s third phase of development is scheduled for 2021-2022 and is expected to focus on the use of AI-assisted diagnostic analysis to increase the efficiency, consistency and accuracy of neurology specialists.

NeuroCap(TM) – Disposable EEG Headset

The NeuroCap is a disposable pre-gelled EEG headset featuring 22 electrodes and 19 active EEG channels, all adhering to the international 10-20 system. The NeuroCap was FDA-cleared in 2018. The headset can be used for recording EEGs in virtually any setting, including urban and rural emergency departments, neurology clinics, urgent care clinics, ICUs, nursing homes, assisted living facilities and remote clinical research labs.

Through a universal cable adapter, the NeuroCap is compatible with other EEG amplifiers. The cap also works in parallel with Brain Scientific’s NeuroEEG amplifier, initiating EEG studies in less than five minutes.

The company is currently seeking FDA approval for additional features for the NeuroCap, as the device has the potential to fill a gap in EEG testing availabilities during the current coronavirus pandemic: in October 2020, Brain Scientific filed an Emergency Use Authorization (EUA) application. The EUA is required for the rapid distribution of the NeuroCap device to emergency departments, intensive care units and other treatment centers to administer prescriptive EEGs safely on critically ill patients or those suspected of being diagnosed with COVID-19.

With more than 80 percent of hospitalized patients infected with COVID-19 displaying neurological symptoms, the NeuroCap could prove to be a valuable device by offering fast testing with limited contact between technicians and patients.

NeuroEEG(TM) – Miniature and Portable Wireless EEG Amplifier

The NeuroEEG is a compact, portable and affordable wireless EEG amplifier intended for prescription use. The 16-channel, FDA-cleared, clinical-grade device acquires, records, transmits and displays electrical brain activity for patients of all ages.

Both the NeuroCap and NeuroEEG are delivered by MemoryMD Inc., a wholly owned subsidiary of Brain Scientific.

Products in Active Development

Currently, Brain Scientific and MemoryMD are working on leveraging their existing products and drawing from ongoing research to develop and commercialize the next generation of solutions for the brain diagnostics market. The devices under development are being designed to address the following issues:

Routine EEG

• NeuroCap-8 is an 8-channel EEG cap. The reduced number of electrodes is vital in emergency room situations, where the time it takes to set up the EEG is critical.

Pediatric EEG

• NeuroCap Pediatric is positioned to become the first disposable and pre-gelled headset available for the pediatric market.

Long-Term Monitoring

• NeuroCap LTM for adult and pediatric patients is a disposable cap designed to monitor rhythmic and periodic patterns for up to 72 hours, providing essential diagnostic capabilities.
• NeuroEEG 24 Channel Amplifier is a portable and wireless amplifier with over 24 hours of battery life.

Artificial Intelligence

• Brain E-Tattoo is a minimally invasive four-channel EEG electrode designed for long-term monitoring.
• An AI database of brain biomarkers collects data on both normal and abnormal brain data to detect neurological diseases. The goal is for machine learning algorithms to enhance understanding of brain-behavior related to epilepsy, memory dementia and pre-Alzheimer’s diagnostics.

Telemedicine

Brain Scientific is expanding the vision for telemedicine in neurology. The company aims to address the current acute neurologist shortfall (20 states have less than 10 neurologists per 10,000 patients) through the use of teleneurology.

 

Partnership with Marketing Brainology

Brain Scientific has a longstanding partnership with Marketing Brainology, a neuromarketing firm using neuroscience approaches to understand consumer behavior. In 2019, Marketing Brainology conducted a study using NeuroCap and NeuroEEG to determine the most effective Super Bowl commercials.

“Thanks to Brain Scientific’s NeuroCap and NeuroEEG, we are able to better understand the art and science of the human decision-making process,” Michelle Adams, Ph.D, Founder of Marketing Brainology, stated in a news release.

In April 2020, Marketing Brainology again conducted a study leveraging Brain Scientific’s disposable EEG cap to determine how brains were reacting to COVID-19 messaging. Subjects were presented with multiple media impressions, and Marketing Brainology analyzed their responsive biomarkers. The results identified the most effective messaging for engaging with an audience during a crisis.

Market Outlook

The current global market for EEG devices is estimated at $956.1 million. It is expected to rise with a CAGR of 8.7% from 2019 to 2026, reaching $1.6 billion in value by 2026, according to Grandview Research.

In total, there are approximately 6,150 hospitals in the U.S., according to the American Hospital Association. Critically, though, just 254 of those hospitals are certified Level 4 Epilepsy centers with 24/7 EEG coverage. Since very few non-Level 4 centers have extensive EEG tech coverage, this creates a significant opportunity for Brain Scientific to bridge the gap by providing over 5,900 hospitals with lower cost amplifiers and disposable EEG caps.

The company also see opportunities to work with other businesses, such as EEG manufacturers hoping to package Brain Scientific’s solutions with their products, which could greatly expand Brain Scientific’s addressable target market.

Management Team

Dr. Baruch “Boris” Goldstein, Ph.D., is co-founder and Chairman of Brain Scientific. He is a seasoned executive with a proven talent for aligning global business strategies with established and emerging management teams. Goldstein’s growth-focused leadership style has helped him raise over $750 million in venture capital for the development of innovative companies and startups in diverse industries, including financial services, biomedicine, alternate energy and new materials, as well as groundbreaking work in artificial intelligence. His recent achievements include important advancements in neurology and unlocking the potential of AI correlations and machine learning applied to life sciences and medical research. He built a suite of first-to-market companies as a technology-oriented leader, including Ryah Medtech, Brain Scientific, GrapheneCA, E-Forex and Intelligent Video Systems. He also co-founded BrainRX, a company specializing in pre-Alzheimer’s diagnostics.

Dr. Nikolay Kukekov, Ph.D., is a Director of Brain Scientific and a partner at HRA Capital. Before joining HRA Capital, Kukekov was Managing Director of Healthcare Investment Banking at Summer Street Research. His scientific background includes a bachelor’s degree in Molecular, Cellular and Developmental Biology from the University of Colorado at Boulder. He earned his Ph.D. in neuroscience from Columbia University – College of Physicians and Surgeons in New York.

Stuart Bernstein is the company’s Vice President of Marketing. He was recently named to the role after spending the first part of his professional career in senior technical management roles with Fortune 500 companies such as NCR (NYSE: NCR), IBM (NYSE: IBM) and Control Data Corp. He was the CEO of BioSignal, an EEG medical device company. He is also a co-founder of several software engineering and telemedicine firms. One of them, Brain Saving Technology, is now Specialist on Call (SOC Telemed) – a leading telemedicine company that powers over 850 facilities for teleneurology, telepsychiatry and critical care telemedicine with over 200 physicians.

Brain Scientific Inc. (OTCQB: BRSF), closed Monday's trading session at $1.60, up 6.6667%, on 799 volume with 5 trades. The average volume for the last 3 months is 3,466 and the stock's 52-week low/high is $0.100000001/$3.00999999.

Recent News

• Brain Scientific Inc. (BRSF) Announces Partnership with Dalmore Group for Upcoming Offering
• Brain Scientific Appoints Stuart Bernstein as VP of Marketing
• Brain Scientific Seeks FDA Approval of Next-Gen NeuroCap(TM) EEG Cap Amidst New Data on Neurological Problems in COVID Patients

Processa Pharmaceuticals Inc. (NASDAQ: PCSA)

The QualityStocks Daily Newsletter would like to spotlight Processa Pharmaceuticals Inc. (NASDAQ: PCSA).

Processa Pharmaceuticals Inc. (NASDAQ: PCSA) was featured today in a publication from BioMedWire, examining how, due to population aging, bone disease is becoming increasingly widespread. This trend has led to an increase in the use of orthopedic and dental implants to treat the condition. We can trace the history of implants all the way back to 1 AD, when wrought iron was fashioned into dental implants in ancient Rome. Despite the long history, various challenges are still linked to implant procedures, including inflammation or a loose implant stemming from slow fusing to the bone tissue. Also today, InvestorWire released a report featuring the company which details various investment considerations and how the company is “One to Watch.” To view the full article, visit https://ibn.fm/afFAa.

Processa Pharmaceuticals Inc. (NASDAQ: PCSA) aims to develop products where existing clinical evidence of efficacy already exists in unmet medical need conditions. In support of this goal, the company has assembled an unparalleled management team, board of directors and product development team featuring experts in developing drug products, from IND-enabling studies to NDA submission. In total, the team’s combined scientific, development and regulatory experience has resulted in more than 30 drug approvals by the U.S. Food and Drug Administration (FDA) and more than 100 meetings with the FDA while working on more than 50 drug development programs, including drug products targeted to orphan disease and unmet medical need conditions.

Headquartered in Hanover, Maryland, Processa has built a pipeline of drugs which already have some proof-of-concept clinical data supporting clinical use in their selected indications.

Development Pipeline

The Processa process focuses on the advancement of drugs that are ready for clinical development or have minimal pre-IND enabling studies to complete. More specifically, Processa:

1. Acquires drugs that already have some clinical data to support the targeted treatment – whether it be the drug itself, an analog of the drug or a drug with similar pharmacological targets;
2. Navigates through the FDA, collaborating with the reviewers to define a complete development program; and
3. Develops each drug over the course of 2-5 years, out-licensing the drug either just prior to pivotal study after Phase 2b or after the completion of the pivotal study.

Processa’s current development pipeline features multiple drug candidates, including PCS499 and PCS100. The company has also announced three additional licensing agreements since June 2020, further bolstering its clinical efforts. Each drug is briefly described below.

PCS6422

On August 27, 2020, Processa announced its entry into a contingent precedent exclusive licensing agreement with Elion Oncology Inc. to develop, manufacture and commercialize eniluracil (PCS6422) globally. PCS6422 is an oral drug to be administered with fluoropyrimidine cancer drugs (e.g., capecitabine, 5-FU) to decrease the breakdown of the cancer drug to inactive metabolites or metabolites that are known to cause unwanted side effects and to increase the anti-cancer related metabolites.

An IND for a Phase 1B study was cleared by the FDA in May 2020. The study will evaluate the safety and tolerability of several dose combinations of PCS6422 and capecitabine in advanced GI tumor patients. Processa intends to enroll the first patient in 1H2021, obtain interim results, and have a final report completed in 2H2022.

“Having worked on 5-FU and other cancer agents in the past, adding PCS6422 to our pipeline and expanding our involvement in oncology was an easy decision given the significant impact that PCS6422 may have on improving the efficacy and safety of capecitabine or other fluoropyrimidines,” CEO Dr. David Young said of the agreement.

PCS499

PCS499 as a potential treatment for necrobiosis lipoidica (“NL”) was first presented to the FDA in a pre-IND meeting in 2018. In 2019, it was the subject of an IND submission and a promising Phase 2 safety study. On March 30, 2020, Processa announced a successful meeting with the FDA regarding the design and execution of the next clinical study to evaluate the ability of PCS499 to completely close ulcers in patients with NL.

“We are pleased with the outcome of the FDA meeting and the feedback we received from the FDA. We believe that the results from our completed Phase 2 trial in NL patients, especially those with more severe ulcerated forms of NL, are encouraging and we appreciate the guidance provided by the FDA regarding our next clinical trial and the requirements to support our NDA submission,” Dr. David Young, CEO of Processa, stated in the news release.

NL is a chronic, disfiguring condition affecting the skin and tissue under the skin, typically on the lower extremities, with no currently FDA-approved treatments. More severe complications can occur, such as deep tissue infections and osteonecrosis, threatening the life of the limb. Approximately 22,500 – 55,500 people in the United States and more than 150,000 – 400,000 people worldwide are affected by the ulcerated form of NL.

YH12852

On August 20, 2020, Processa announced its entry into an agreement with Yuhan Corporation, a South Korean firm, to license YH12852, a small molecule drug in development for the treatment of functional gastrointestinal (GI) disorders. Under the terms of the agreement, Processa will acquire the rights to a portfolio of patents with an exclusive license to develop, manufacture and commercialize YH12852 globally, excluding South Korea.

YH12852 is a novel, potent and highly selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist. Other 5-HT receptor agonists with less 5-HT4 selectivity have been shown to successfully treat GI mobility disorders such as chronic constipation, constipation-predominant irritable bowel syndrome, functional dyspepsia and gastroparesis. The less selective 5-HT4 agonists, such as cisapride, have been removed from the market because of the cardiovascular side effects associated with the drugs binding to other receptors, especially 5-HT receptors other than 5-HT4.

CEO Dr. David Young called the agreement “further evidence of Processa’s commitment to seek out novel treatments for unmet medical conditions.” Processa intends to meet with the FDA in early 2021 to further define the clinical development program. In 2021, Processa expects to initiate a Phase 2 trial in a functional GI motility-related disorder that that needs better therapeutic options, such as postoperative ileus and opioid-induced constipation.

ATT-11T

On June 1, 2020, Processa announced its entry into a licensing agreement with Aposense Ltd. for the patent rights and know-how to develop and commercialize ATT-11T, a next generation irinotecan cancer drug. In the release, CEO Dr. David Young noted that the licensing deal fit with Processa’s strategy to “continue to bring innovative products to patients with an unmet medical need condition.”

ATT-11T is a novel lipophilic anti-cancer pro-drug that is being developed for the treatment of the same solid tumors as prescribed for irinotecan. This pro-drug is a conjugate of a specific proprietary Aposense molecule connected to SN-38, the active metabolite of irinotecan. The proprietary Aposense molecule on ATT-11T allows ATT-11T to bind to cell membranes to form an inactive pro-drug depot on the cell, with SN-38 preferentially accumulating in the membrane of tumors cells and the tumor core. This unique characteristic is expected to make the therapeutic window of ATT-11T wider than irinotecan, such that the anti-tumor effect of ATT-11T will occur at a much lower dose than irinotecan with a milder adverse effect profile than irinotecan. The wider therapeutic window will likely lead to more patients responding with less side effects when on ATT-11T compared to irinotecan.

The ATT-11T licensing agreement is conditioned upon Processa’s closing of a satisfactory financing round and the listing of the company’s shares on the Nasdaq or NYSE, among other conditions.

PCS100

On September 3, 2020, Processa announced its entry into an exclusive worldwide license agreement with Akashi Therapeutics to develop and commercialization Akashi’s lead drug, HT-100. Rebranded PCS100, the candidate is an anti-fibrotic, anti-inflammatory drug demonstrated to have some clinical anti-fibrotic effect in children. Processa intends to develop PCS100 first in rare adult fibrotic related diseases such as focal segmental glomerulosclerosis (FSGS), idiopathic pulmonary fibrosis (IPF) or Scleroderma, where there are still few therapeutic options.

Management Team

David Young, Pharm.D., Ph.D. is the CEO and founder of Processa. He has over 30 years of pharmaceutical research, drug development and corporate experience. Young has served in leadership roles with a number of pharmaceutical firms throughout his career, including serving as founder and CEO of Promet Therapeutics LLC since 2015 and as Chief Scientific Officer of Questcor Pharmaceuticals from 2009 to 2014. At Questcor, he was responsible for working with the FDA on modernizing the Acthar Gel label and for obtaining FDA approval in infantile spasms. In total, Young has met with the FDA more than 100 times on more than 50 drug products and has been a key team member on more than 30 NDA/supplemental NDA approvals.

Sian Bigora, Pharm.D., is Processa’s Chief Development Officer and founder. She has over 20 years of pharmaceutical research, regulatory strategy and drug development experience, working closely with Young. Prior to joining Processa, Bigora served as Co-Founder, Director and Chief Development Officer at Promet Therapeutics LLC and as Vice President of Regulatory Affairs at Questcor Pharmaceuticals from 2009 to 2015, where she led efforts to modernize the Acthar Gel label and obtain FDA approval in infantile spasms – events which were of material importance to Questcor’s subsequent success.

Patrick Lin is Chief Business & Strategy Officer and founder of Processa. He has over 20 years of financing and investing experience in the biopharma sector. Prior to joining Processa, Lin served as Co-Founder and Chairman of Promet Therapeutics LLC. He is also founder and managing partner of Primarius Capital, a family office that manages public and private investments focused on small capitalization companies.

James Stanker has served as CFO of Processa since 2018. He has over 30 years of financial and executive leadership experience in the areas of accounting principles and audit standards, regulatory reporting, and fiscal management and strategy. He served in a financial leadership role as an audit partner at Grant Thornton from February 2000 until his retirement in August 2016, where he was responsible for managing audit quality in the Atlantic Coast market territory.

Wendy Guy is the Chief Administrative Officer and founder of Processa. She has more than two decades of experience in business operations, having worked closely with Young over the last 18 years in corporate management and operations, HR and finance. Prior to joining Processa, she was Co-Founder, Director and Chief Administrative Officer of Promet Therapeutics LLC and Senior Manager, Business Operation over the Maryland office for Questcor Pharmaceuticals.

Processa Pharmaceuticals Inc. (NASDAQ: PCSA), closed Monday's trading session at $4.16, up 1.2165%, on 34,066 volume with 117 trades. The average volume for the last 3 months is 27,417 and the stock's 52-week low/high is $3.40000009/$18.00.

Recent News

• Korean Researchers Develop Artificial Coating to Avert Bone Inflammation
• Why Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Is 'One to Watch'
• Biomedical Engineer Invents Technique That May Help Improve Eyesight

GoldHaven Resources Corp. (CSE: GOH) (OTCQB: ATUMF)

The QualityStocks Daily Newsletter would like to spotlight GoldHaven Resources Corp. (CSE: GOH) (OTCQB: ATUMF).

GoldHaven Resources Corp. (CSE: GOH) (OTCQB: ATUMF) was featured today in a publication from MiningNewsWire, examining A recent report, which revealed that China’s advancement of its new infrastructure plan, which involves beneficiation, will increase the production of high-end metals. The focus on advanced infrastructure has been more active after the decrease in economic activity as a result of the coronavirus pandemic and the heightened tensions between China and the United States. Also today, the company was featured in a publication from MiningNewsWire, examining today’s announcement that, per its stock option plan, it has granted an aggregate of 1,850,000 incentive stock options to directors, officers and advisors of the company. According to the update, the stock options will vest immediately and be exercisable to purchase one common share in the capital of the company on or before November 2, 2025, at a price of $0.42 per share. To view the full press release, visit http://ibn.fm/8SzUs

GoldHaven Resources Corp. (CSE: GOH) (OTCQB: ATUMF) (formerly Altum Resources Corp.), a Canada-based company engaged in the business of acquiring and exploring mineral resource properties, recently announced its entry into agreements to acquire seven advanced gold projects in the Maricunga Gold Belt of Chile that hosts over 100 million ounces of gold within the last 10 years.

Chilean Gold Properties Being Acquired

On April 17, 2020, GoldHaven Resources entered into an agreement to purchase a 100% interest in two gold projects located in the Maricunga Gold Belt of Northern Chile. The first property, Rio Loa, is located 25 kilometers south of Gold Fields Ltd.’s Salares Norte, where, this year, a five-million-ounce discovery was made. The second property, Coya, is located only 10 kilometers east of the Kinross La Coipa open pit mine, which has produced over 7.5 million ounces of gold to date.

Rio Loa Project

Initial geophysical studies of the Rio Loa site have exposed highly anomalous ardennite and lead values, a key characteristic of gold mineralization within silicified resistive bodies. The studies have also produced initial findings which are similar to those seen at contiguous mines, such as Salares Norte (operated by Gold Fields), which has over five million ounces in estimated gold deposits.

The potential economics for the site look particularly promising when taking the unit costs at the neighboring Salares Norte mine into account. Gold Fields has estimated that its production AISC (all-in sustainable costs) will approximate $552 per ounce and have forecast a 2.3-year payback period for its initial investment, assuming a $1,300 per ounce gold price.

Coya Project

The Coya site is located within close proximity to one of the richest and largest epithermal gold and silver districts in Chile and is in close proximity to active mining sites, specifically the La Coipa mine owned by Kinross. A study carried out in 2017-2018 on the Coya site of 796 rock chip samples found favorable gold and silver values, in some cases ranking as high as 764 grams/tonne of gold and 719 grams/tonne of silver – values which are near certain indicators of potential gold and silver deposits. The La Coipa mine (Kinross) has produced over 6.9 million ounces of gold to date.

On August 11, 2020, GoldHaven Resources acquired five potential gold projects in the Maricunga Gold Belt of Northern Chile. The Maricunga hosts discoveries within the last 10 years of over 100 million ounces of gold and over 450 million ounces of silver. These newly acquired properties are in close proximity to seven other mines, which possess an estimated aggregate of 81 million ounces of gold in total reserves.

GoldHaven’s five new projects cover a total area of approximately 22,600 hectares, or 226 square kilometers, located in the northern portion of the Maricunga Belt in proximity to the 5 million-ounce gold equivalent Salares Norte project owned by Gold Fields. Gold Fields announced in April 2020 its intention to proceed with the development of Salares Norte at a cost of $860 million, with a $138 million expenditure budgeted for 2020.

The Maricunga Belt extends approximately 150 kilometers north-south and 30 kilometers east-west, straddling the border between Chile and Argentina. This region hosts known mineral resources of more than 100 million ounces of gold, 450 million ounces of silver and 1.3 billion pounds of copper.

The Maricunga project’s opportunity came about as a result of a $150 million initiative launched by the Chilean Economic Development Agency (“CORFO”), with the objective of encouraging exploration and mining prosperity in Chile and strengthening Chile’s position as a world leader in the sector.

As part of CORFO’s program, a total of $15.3 million was given to private equity fund IMT Exploration to evaluate 403 projects, beginning in 2011. This led to a generative program carried out from 2016 to 2019, resulting in 126 potential epithermal targets from which 57 field evaluations were made. Due diligence work followed on 19 of these. Work programs were then conducted, including geological mapping, rock and soil sampling and TerraSpec (PIMA) analyses on geochemical grids for alteration mapping, and, as a result, the five high-priority Maricunga projects were identified. No drilling has been carried out on any of the Maricunga projects.

Securing Financing for Upcoming Operations

In conjunction with its announcement regarding its acquisition of five Chilean mining interests, GoldHaven Resources also detailed plans for a non-brokered private placement of 11.5 million units at a price of $0.35 per unit, for gross proceeds of $4,025,000. Each unit will consist of one share of the company and one warrant, the latter of which can be exercised to acquire an additional share of the company for a period of 18 months from the date of issuance at a price of $0.50 per share. Net proceeds from the offering are intended to be used to fund general expenses, as well as exploration and drilling of its mineral properties.

Gold Prices Hit Record High in 2020

Gold prices have been on a remarkable run in 2020, breaking above $2,000 per ounce for the first time on record. Having begun the year at $1,515 per ounce, the precious metal has seen a huge surge on the back of widespread economic uncertainty stemming from governments’ worldwide propensity to expand the money supply, from the reduction of the value of the U.S. dollar as expressed by the decrease in the U.S. dollar index, and from the very real economic effects of the COVID-19 pandemic.

Global central banks have carried out 144 interest rate cuts thus far in 2020, reducing rates by a cumulative 5,035 basis points (http://nnw.fm/jzZt0). Meanwhile, the IMF has estimated that global governments have introduced fiscal support measures amounting to over $9 trillion since the start of the pandemic (http://nnw.fm/Or9rI). The resulting weakness in the U.S. dollar and eventual inflationary pressures stemming from these measures has prompted a number of investment banks to boost their near-term outlooks for gold prices, with Bank of America raising its 18-month gold price target to $3,000 per ounce (http://nnw.fm/PQJtc).

Leadership Team

David Smith, President, CEO and Director, has been immersed in the mining industry for the last eight years, working in corporate development and finance. Prior to GoldHaven Resources, Smith cofounded a multifaceted real estate development and sales company, which has now been in operation for over 35 years. He also cofounded two successful environment-focused companies listed on the Toronto Stock Exchange. Both companies were sold independently and returned a significant profit for shareholders.

Darryl Jones, Chief Financial Officer, is a finance executive and CPA with over 30 years of public company and project buildout experience. Most recently, Jones served as the CFO of Lupaka Gold Corp., retiring in June 2018. Prior to that, Jones serves as CFO of Corriente Resources, which was sold to CRCC-Tongguan in May 2010 for C$680 million.

Patrick Burns, VP Exploration and Director, is a Canadian geologist with over 40 years of experience throughout the Caribbean and Central and South America. He played a direct role in the discovery of the Escondida porphyry copper deposit in Chile and has been involved in publicly traded mining companies, predominantly in Chile, for 35 years.

Marla Ritchie, Corporate Secretary, brings over 25 years of experience in public markets to the GoldHaven team. Throughout this time, she has worked as an administrator and corporate secretary specializing in resource-based exploration companies. Currently, Ritchie is the corporate secretary for several companies, including International Tower Hill Mines Ltd. and Trevali Mining Corp.

Gordon Ellis, Director; has over 50 years’ experience in mining and resource development. A professional engineer and entrepreneur, he has held multiple senior management and director roles with public mining companies, as well as a multi-billion-dollar ETF fund. Ellis holds an MBA in international finance and a Chartered Directors designation.

Scott Dunbar, Director is a professor and head of multiple departments at the University of British Columbia, including mineral extraction and mining innovation, as well as mining engineering. He has been involved in projects around the world in regard to mining exploration, geotechnical engineering and mine design. Dunbar received his PhD in geophysics and civil engineering from Stanford University.

GoldHaven Resources Corp. (OTCQB: ATUMF), closed Monday's trading session at $0.32, up 0.882724%, on 80,150 volume with 19 trades. The stock's 52-week low/high is $0.109999999/$0.446000009.

Recent News

• China's Ambitious Infrastructure Plan Will Grow Metals Demand
• GoldHaven Resources Corp. (CSE: GOH) (OTCQB: ATUMF) Announces Granting of Stock Options, Appointment of New CEO
• GoldHaven Resources Corp. (CSE: GOH) (OTCQB: ATUMF) Cites 2020 as Year of Milestones

Net Element (NASDAQ: NETE)

The QualityStocks Daily Newsletter would like to spotlight Net Element (NETE).

Net Element (NASDAQ: NETE) was featured today in a publication from Green Car Stocks, examining how the UK is one of numerous countries that have pledged to phase out internal combustion-powered vehicles in favor of electric vehicles (“EVs”). In summer 2019, then Prime Minister Theresa May signed into law the groundbreaking target of achieving net-zero carbon emissions by 2050. However, one factor that has consistently stood in the way of widespread EV adoption, especially in the less-affluent boroughs of London, is poor charging infrastructure.

On June 15, 2020, Net Element announced its entry into a binding letter of intent to merge with privately-held Mullen Technologies Inc., a Southern California-based electric vehicle company, in a stock-for-stock reverse merger in which Mullen’s stockholders will receive the majority of the outstanding stock in the post-merger company. The proposed merger is currently pending the execution of a definitive agreement, shareholder vote and regulatory approval.

Net Element Inc. (NASDAQ: NETE) is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce and mobile devices. The company operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the U.S. and selected emerging markets.

Net Element believes the future of global commerce is being revolutionized as consumers quickly migrate toward omni-channel shopping utilizing mobile devices, desktop, and online services. The company’s all-in-one payment solutions support and unify a whole range of applications through a single, robust platform, allowing global onboarding and support for multiple payment methods.

Net Element has also launched a blockchain-focused business unit that will develop and deploy blockchain technology-based solutions. Net Element expects the new division to create a decentralized crypto-based ecosystem that will act as a framework for an unlimited number of value-added services, connecting merchants and consumers in a seamless, economically efficient transaction. This new business unit intends to also identify and invest in unique projects that decentralize and disrupt the payment processing industry by combining blockchain technology and real-world applications with talented development teams, strong fundamentals and addressable markets large in size.

“We believe that we’re at the dawn of a new evolution where additional digital payment methods are being introduced,” Net Element chairman and CEO Oleg Firer, says. “Introduction of our division focused on blockchain as part of the NASDAQ-listed entity will add transparency and compliance assurance to our investors as well as provide access to deploy value-added services to over 20 million electronic commerce clients that are currently part of Net Element’s growing network.”

Net Element clients are treated to customized solutions that provide the flexibility needed to keep up with customers. Among the services offered are mobile payment apps that accept payments anywhere, anytime; cloud-based solutions built to increase productivity and enhance revenue for clients and partners; marketing solutions that turn lookers into buyers; and business analytics that make it easy for clients to monitor business metrics, engage with customers and compare the competition. Its multi-channel platform combines e-commerce, offline, point-of-sale, comprehensive back office tools, mobile point-of-sale, credit scoring and customer interaction in one powerful platform-as-a-service technology.

Net Element owns and operates a global mobile payments and transactional processing provider, TOT Group, Inc., with the following subsidiaries:

• Unified Payments – An award-winning, customized mobile billing and payments solution, recognized by Inc. Magazine as the No. 1 Fastest Growing Company in America in 2012.
• Aptito – A next-generation, all-in-one, cloud-based restaurant management and point-of-sale payments platform using wireless technology.
• Payonline – A fully integrated, processor agnostic electronic commerce platform.

Net Element is ranked on Deloitte’s Technology Fast 500™ list of North America’s 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in both 2017 and 2018, during which the company grew 190 percent and 183 percent, respectively. The company credits its progression to organic growth in its North America Transactions Segment, specifically the success of its Unified Payments brand, which focuses on value-added payment acceptance solutions for small to medium enterprises in the United States.

Net Element was also listed among South Florida Business Journal’s 2016 fastest growing technology companies.

Leveraging its suite of application performing interfaces (APIs) and connectors, Net Element powers commerce for businesses of all sizes through multi-channel platforms, all-in-one digital solutions, and end-to-end encryption of cardholder data utilizing tamper resistant hardware that ensures integrity and simplifies security.

Leading this innovation is chairman and CEO Oleg Firer, who is responsible for the overall vision, strategy and execution of the company’s mission of powering global commerce. He is joined by CFO Jeffrey Ginsburg, CPA, and Steven Wolberg, the company’s chief legal officer and secretary. Each corporate officer brings a unique blend of leadership, vision, experience and creative energy to the company.

From mobile payments and value-added transactional innovations like Aptito to e-commerce and retail payment transaction processing brands like Payonline and Unified Payments, Net Element is transforming the online and mobile experience.

Net Element (NETE), closed Monday's trading session at $6.17, up 4.932%, on 252,925 volume with 1,434 trades. The average volume for the last 3 months is 1,334,290 and the stock's 52-week low/high is $1.472/$20.0783996.

Recent News

• Uber Technologies Inc. (NYSE: UBER) Commits $6.5 Million to Building EV Charging Stations in London
• The Benefits, Drawbacks of Buying Used Electric Vehicles
• EV Battery Makers Need to Consider Recycling Needs to Avert Waste Crisis

Knightscope, Inc.

The QualityStocks Daily Newsletter would like to spotlight Knightscope, Inc..

Knightscope is a leader in the development of autonomous security capabilities. The company designs and builds Autonomous Security Robots (“ASRs”), which use Knightscope’s proprietary technology combining robotics, self-driving technologies, and artificial intelligence. The ASRs have proven to enhance the safety at hospitals, manufacturing plants, logistics facilities, schools, businesses, parking lots, and corporate campuses. This level of versatility enables Knightscope to disrupt the $500 billion security industry by offering reliable and cost-effective security solutions for a wide range of scenarios and locations – even during a pandemic. Knightscope currently has three models on the market, with one currently in long-term development – which all drive over 90 terabytes a year of data per machine to an intuitive browser-based user interface.

Knightscope, Inc., founded in 2013 and based in Mountain View, California, is a leader in the development of autonomous security capabilities and are on target to disrupt the $500 billion security industry. Knightscope’s technology uniquely combines self-driving technology, robotics and artificial intelligence.

Knightscope designs and builds Autonomous Security Robots (ASRs) that provide 24/7/365 security to the places you live, work, visit and study. The company’s client list covers public institutions and commercial business operations, including ten Fortune 1000 companies to date. These ASRs have been proven to enhance safety at hospitals, logistics facilities, manufacturing plants, schools and corporations. ASRs act as highly cost-effective complementary systems to traditional security and law enforcement officials, providing an additional advantage by continuing to offer uninterrupted patrolling capabilities across the country, despite the pandemic (note: robots are immune).

The company’s ASRs have assisted in the arrest of suspects involved in crimes ranging from armed robbery to hit-and-runs. Their machine-embedded thermal scanning capability even aided in preventing the breakout of a major fire.

The company has achieved several milestones since its creation in 2013, including:

• Establishing itself in a 15,000-square-foot facility located in Mountain View, California, in the heart of Silicon Valley, where Knightscope designs, engineers and builds its technology;
• Operating for more than one million hours in the field and securing contracts across five time zones;
• Navigating through the global pandemic without interruption by continuing to operate on a daily basis across the nation and supporting clients classified as essential services; and
• Continuing its hiring processes despite the current societal and economic disruption.

Growth Capital

With more than 10,000 investors and over $40 million raised since inception, Knightscope is poised to be an industry leader in the future of public safety and security.

The company is presently in the process of raising up to $50 million in growth capital as it prepares for a potential public listing. Knightscope has reserved ticker symbol ‘KSCP’ with Nasdaq.

Investors can buy shares exclusively through the company’s managing broker-dealer, StartEngine (http://nnw.fm/l9GLX) until July 20, 2020. Concurrent with this live offering and contingent upon various factors, including raising a sufficient amount of funds and meeting applicable listing standards, the company intends to begin preparation of an S-1 format Form 1-A and Nasdaq Capital Market application in anticipation of a possible public listing of the stock at the conclusion of the Regulation A+ offering.

Company Mission — The Greater Good

Knightscope’s long-term vision has an eye on the greater good. The company’s mission is to make the United States of America the safest nation in the world while supporting millions of law enforcement and security professionals across the country.

Crime has a negative economic impact in excess of $1 trillion annually. As crime is reduced, positive impacts will likely be realized across several aspects of society, including housing, financial markets, insurance, municipal budgets, local business and safety in general.

Knightscope CEO William Santana Li was recently interviewed by Kevin O’Leary, more commonly known as Shark Tank’s Mr. Wonderful. When asked to explain how the benefits provided by the ASRs outrank a human doing the same job, Li said, “First, just the simple presence of a physical deterrent causes criminal behavior to change. Second, the machines are self-driving cars that patrol all around and recharge themselves. They also generate 90 terabytes of data per year. No human would ever be able to process that. The robots are intended to be eyes and ears for the humans, not a one to one replacement.”

The Knightscope solution to reduce crime combines the physical presence of ASRs, sometimes referred to as proprietary Autonomous Data Machines, with real-time onsite data collection and analysis. The ASRs are fitted with eye-level 360° cameras, thermal scanning, public address announcements and various other features that work in tandem with humans to provide law enforcement officers and security guards unprecedented situational awareness.

Those 90 terabytes of data are then formatted in a useable way, so law enforcement can leverage that information and execute their responsibilities more effectively.

Public Safety Innovation

The company’s recurring revenue business model is set up to mimic the recurring societal problem of crime, and it takes into consideration the fact that innovation in the security and public safety industry has been stagnant for decades. Because the traditional practices of the sector have remained unchanged for years, automation has potential to drive substantial cost savings — and significant improvement in capabilities.

Human security guards are one of both the largest expenses and the largest liabilities for companies. Knightscope’s robots are offered at an effective price of $4 to $11 per hour, compared with approximately $85 and $30 per hour for an armed off duty law enforcement officer and an unarmed security guard, respectively.

This innovation has the potential to drive considerable cost savings. Based on these estimates, manufacturing costs can be recovered as soon as the first year of operation.

Product Offerings

The company has four patents and a framework of unique intellectual property. Knightscope currently offers a K1 stationary machine, a K3 indoor machine and a K5 outdoor machine. A K7 multi-terrain four-wheel version is in development.

The ASRs autonomously patrol client sites without the need for remote control, providing a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area and deter crime. The data is accessible through the Knightscope Security Operations Center (KSOC), an intuitive, browser-based interface that enables security professionals to review events generated by the ASRs providing effectively ‘mobile smart eyes and ears’.

The ASRs and all the related technologies were developed ground up by the Company and are Made in the USA.

Management Team

Chief Executive Officer William Santana Li is a veteran entrepreneur, a former executive at Ford Motor Company and the founder of GreenLeaf, a company that grew to be the world’s second-largest automotive recycler and is now part of LKQ Corporation (NASDAQ: LKQ).

Chief Client Officer Stacy Dean Stephens brings his experience as a former Dallas law enforcement officer, as well as his skills as a seasoned entrepreneur, to assist on the client acquisition side.

Chief Intelligence Officer Mercedes Soria is an award-winning technologist and former Deloitte software engineer.

Chief Design Officer Aaron Lehnhardt brings over two decades of two- and three-dimensional product and industrial design in modeling and VR to the table, on top of his experience as a senior designer at Ford Motor Company.

Recent News

• Knightscope, Inc. Creating Change in the Security Industry Through Proprietary Technology to Assist Law Enforcement and Private Security
• Knightscope Inc. Appoints Experienced Financial Exec as CFO, Announces Online Opportunity to Invest
• Knightscope, Inc. Becomes Single Biggest Round on StartEngine to Date

Cybin Corp.

The QualityStocks Daily Newsletter would like to spotlight Cybin Corp..

Cybin Corp., a Canada-based, life-science company advancing psychedelic pharmaceuticals, recently announced the appointment of Doug Drysdale as its CEO (https://ibn.fm/UTTdr). Drysdale, named an Ernst and Young Entrepreneur of the Year in 2012, brings more than three decades of experience in the health-care sector and will continue to grow the company’s IP portfolio. “With his myriad of business accomplishments, Doug is the ideal leader for Cybin,” stated Cybin co-founder and COO Paul Glavine of the appointment. To view the full article, visit https://ibn.fm/sSqkf

Cybin Corp. is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Recent News

• Cybin Corp. Paves Path to Profitability with Health-Care Veteran at the Helm
• Cybin Corp. Appoints New CEO with Impressive Health-Care Expertise
• Cybin Corp. Holds Distinct Strength in Psychedelics Space

Pac Roots Cannabis Corp. (CSE: PACR)

The QualityStocks Daily Newsletter would like to spotlight Pac Roots Cannabis Corp. (PACR).

The U.S. manufacturer for a novel anthracycline being tested by biopharmaceutical company CNS Pharmaceuticals (NASDAQ: CNSP) as a potential new strategy in combatting an inexorable and ultimately fatal type of brain tumor has completed the manufacturing process for the drug candidate, known as Berubicin. CNS Pharmaceuticals, with its sublicensee partner WPD Pharmaceuticals, is also preparing for 2 clinical trials in Poland including the first Phase 1 pediatric trial of Berubicin and a parallel Phase 2 trial in adults. Berubicin has shown promise in combatting Glioblastoma multiforme, an aggressive form of brain cancer commonly regarded as incurable. One participant in Berubicin’s Phase 1 trial remains cancer-free 14 years after the trial.

Pac Roots Cannabis Corp. (CSE: PACR) is a Canadian cannabis company dedicated to producing premium-quality strains and products by leveraging a genetics-focused approach.

The company began operations in 2012, with activities primarily directed toward exploration and development of mineral properties in Canada. Today, it is focused on cannabis and hemp cultivation, leveraging high-end genetics and specialized cultivars to produce top quality products. Pac Roots has announced multiple promising initiatives in recent months, including its formation of an outdoor premium hemp joint venture with partner Rock Creek Farms in British Columbia, Canada, and its agreement to acquire all issued and outstanding shares of a firm holding 250 acres of land in the famed Fraser Valley Region of British Columbia.

Pac Roots is also in the process of completing its 20,000 square foot cultivation facility in Lake Country, British Columbia. The facility is expected to feature approximately 7,600 square feet of cultivation space that will enable the company to cycle through an elite line of 350+ unique, high-grade cultivars. Pac Roots expects to receive a cultivation license for the facility in the fourth quarter of 2020.

High-End Selectively Bred Genetics

Pac Roots focuses on high-end genetics in order to maximize the quality of its products while maintaining high yields and profit margins.

Through the process of artificial selection, farmers and cultivators have been adapting their plants to develop particular phenotypic traits for generations. Historically, this practice was restricted to underground cannabis producers developing their own strains.

The legalization of the cannabis industry has given producers access to thousands of cultivars located throughout the world while accelerating research into cannabis genetics. By carefully selecting strains, growers can control the size, color, smell, density and texture of cannabis buds, thereby creating distinctive, premium cannabis products.

Plants are bred to thrive in specific growing environments. This maximizes the yield of high-quality, resilient cannabis. Medical cannabis strains can also be tailored for specific medicinal purposes.

A strategic partnership with Phenome One, a plant breeding management and analytics firm, gives Pac Roots access to some of the world’s best cannabis genetics from the largest genetic library in Canada. The company is using these genetics to develop unique strains featuring a variety of beneficial characteristics.

The company’s 350+ licensed live cultivars and over 1,800 seed varieties are the result of a meticulous gene selection process, through which as many as 600 individual plants may be grown to produce a single strain. Selecting optimized genetics in this way provides benefits beyond simply producing a high-end product. In addition to potency and bud quality, cannabis plants are bred for yield and resilience. By selecting genetics that result in larger and more numerous buds on each plant, Pac Roots is able to grow more cannabis per grow light.

Breeding plants to be more resilient also reduces the cost and labor required. These factors, combined with the premium price point associated with top-quality cannabis, have the potential to improve Pac Roots’ overall profit margin.

Partnership with Phenome One

Pac Roots has secured its cultivars through a strategic licensing agreement with Phenome One. Under the agreement, Pac Roots has unlimited access to Phenome One’s live genetic library, including any of Phenome One’s cultivars and its growing, breeding and cloning IP.

Phenome One is an agricultural technology company focused on providing software solutions to seed companies. Phenome One’s platform gives its partners access to a massive database of detailed information on over 350 unique cannabis cultivars to support each stage of the breeding process. Each cultivar has been laboratory analyzed and rigorously field-tested, with data going back more than 30 years.

Using Phenome One’s data, Pac Roots plans to grow a variety of cannabis plants optimized for certain traits. One such trait will be plants with an abundance of cannaflavin, a rare terpene with high anti-inflammatory properties. Phenome One’s library could enable Pac Roots to produce plants that are bred to thrive in a range of different growing climates, including plants suited to grow in cold weather and plants that are resilient to region-specific fungi.

Joint Venture with Rock Creek Farms of British Columbia

Pac Roots recently entered a definitive investment agreement with Rock Creek Farms, a reputable agricultural enterprise, for a 100-acre commercial hemp operation in Rock Creek, British Columbia. The growing space is located in the highly lucrative farming area known as the ‘Golden Mile’ in the South Okanagan Valley of British Columbia. (http://nnw.fm/Gbf9I).

Under the agreement, the two companies have formed an outdoor premium hemp joint venture company to which Pac Roots is providing an aggregate of $450,000 in capital and Rock Creek Farms is contributing two commercial leases for 100+ acres of growing space, along with cultivation licenses, agricultural infrastructure and equipment, consulting services, intellectual property relating to hemp operations and proprietary biomass storage methods. Pac Roots holds a 60 percent interest in the project.

About 127,500 premium hemp CBD seedlings were planted across 100 acres as of early July 2020. The joint venture is planting a premium grade CBD hemp variety utilizing the rich native soil and both traditional and custom farming techniques.

“Our operational partners at Rock Creek Farms bring decades of generational farming expertise in one of Canada’s pre-eminent growing regions,” Pac Roots President and CEO Patrick Elliott said in a news release detailing the venture. “It will be an exciting outdoor growing season for the joint venture as we anticipate a successful harvest in the fall.”

Infinite Development Possibilities at Fraser Valley Property in British Columbia

In mid-July 2020, the company initiated a share purchase agreement with 1088070 BC. LTD. (“1088”) and its shareholders for the acquisition of all issued and outstanding shares of 1088 (http://nnw.fm/xlpw7). Notably, 1088 owns and controls 250 acres of land spread over nine parcels in the Fraser Valley Regional District.

The Fraser Valley Regional District is one of the most productive and intensively farmed areas of Canada, offering access to high-quality soil, favorable climate, water and a local market of 2.5 million people. Agriculture in this region yields an annual economic value of more than $3 billion.

The closing date for the transaction is slated for September 4, 2020, after a 51-day due diligence period. According to Elliott, the addition of such a significant package of land is a major step for Pac Roots.

“This land has no zoning restrictions and is not situated within the agricultural land reserve, which provides for infinite development possibilities,” Elliott added in a July 2020 news release.

Board of Directors member Chad Clelland also welcomed the acquisition, adding that between Fraser Valley and Rock Creek – both of them among the most productive agricultural regions in Canada – Pac Roots is very well positioned for production and the future development of its hemp and cannabis infrastructure.

The RAD Americas Genetic Program – Research and Development in Americas Genetic Program

Pac Roots intends to deploy a global R&D program focused on rigorously testing elite strains in various rich agricultural regions throughout the Americas, with a goal of mass selection to achieve the utmost environmental resilience while achieving notable quality and yields. From seed to software, collection data, proprietary techniques and custom nutrient formulas, Pac Roots and Phenome will provide the specific knowledge to cultivators in different climates in order to achieve optimal yields for THC, CBD, CBG and other unique cannabinoids. R&D from global testing programs situated throughout the Americas will allow the partnership to deploy and stress test a range of suitable cultivars in the world’s lowest cost outdoor growing regions.

The company expects an industry shift in 2020 from the COVID-19 global pandemic. The ‘new normal’ will bring more focus on efficiencies and optimal yields to deliver a cost effective, high quality product to the end user. There has been much to be learnt from the inefficiencies in the cannabis industry in recent years, which have been detrimental to the credibility of the sector. Pac Roots is well positioned to enter the scene and take advantage of the deficiencies, reinforcing the notion that genetics and flawless growing techniques are paramount to success. Genetics and systems innovation may be the most overlooked components when comparing cannabis to other established agricultural crops. Pac Roots plans to invest into cannabis R&D to ensure a solid foundation is built that will be used by cannabis farmers worldwide.

Through its RAD Americas Development and Innovation, Pac Roots is focused on:

• Deploying one of the largest live genetic libraries in Canada, diversified for high yield output and unique climates
• Continued stress testing for indoor, high yield, THC and medicinal genetics
• Continued stress testing for outdoor, high yield, THC and medicinal genetics
• Exotic, genetic cloning for the luxury, high margin, cannabis flower market
• Psychoactive/medicinal ratio testing for effect and
• Unique Cannabinoid and terpene elevation and isolation.

Through its RAD Americas Field Testing System, the company is focused on:

• Global testing in different microclimates to assess genetic and complete systems for optimal yields
• Data collection, testing and optimization to prove process for commercial implementation and
• High quality yield testing for THC, CBD, CBG and other unique medicinal cannabinoids.

Lake Country Cultivation Facility near Kelowna, British Columbia

Pac Roots is in the process of completing its 20,000 square foot cultivation facility in Lake Country, British Columbia. The facility is expected to feature approximately 7,600 square feet of cultivation space that will enable the company to cycle through its line of high-grade cultivars. Pac Roots plans to submit a video evidence package of the facility build under Health Canada’s Cannabis Tracking and Licensing System, and the company expects to acquire its cultivation license in the fourth quarter of 2020.

Lake Country is a municipality located just outside of Kelowna in the Okanagan region of British Columbia. For decades, the region’s favorable growing climate has made it a hub for cannabis cultivation. As the Canadian legal cannabis industry ramps up, the Okanagan region is attracting attention from dozens of cannabis companies, including some of the industry’s biggest names. The region’s strong agricultural history has left it rich with experienced agricultural workers and an abundance of Agricultural Land Reserve (ALR) property.

Management Team

Patrick Elliott, MSC, MBA, President and CEO of Pac Roots Cannabis, is also the President & CEO of Lexore Capital Corp., a private resource and cannabis investment company, as well as Phenome One Corp., a full-service cannabis farming company focused on elite strain selective breeding. Elliott brings over 15 years of corporate finance, mineral exploration and financial markets experience to the Pac Roots team. He is a graduate of the University of Western Ontario in geology and holds an MSc. in mineral economics and an MBA from Curtin University of Technology in Perth, Australia. Elliott specializes in economic resource evaluation, financial modeling, CAPEX estimation, corporate development and finance. Combined with his technical knowledge, Elliott has a wealth of contacts in the financial sector.

Marc Geen, Founder and Strategic Operations Advisor, is a fourth-generation British Columbia farmer who has been active in the legal medical marijuana industry for more than 10 years – consulting on, complying with, and participating in the MMAR, MMPR and ACMPR programs. Prior to co-founding Speakeasy Cannabis Club Ltd., Geen spent 14 years as Head of Operations for Kettle Mountain Ginseng Ltd., one of North America’s largest ginseng producers. With the experience gleaned from a long career in large scale commercial farming, Geen has been able to apply many cost-effective farming practices to the outdoor, indoor and greenhouse cultivation of cannabis. Geen is also the co-creator of a full line of cannabis extract products designed under ACMPR regulations.

Matt McGill, Director, has a strong background in both commercial and residential real estate and has played a major role in many development projects. McGill, through McGill Realty, has established a tremendous commercial and residential outfit servicing British Columbia’s Fraser Valley and the lower mainland. McGill is skilled at crafting strategic financing options for corporations and has a substantial network of retail and institutional clients.

Chad Clelland, Director, has experience in the sector dating back to 2009, when he purchased Medicalmarijuana.ca, which became an information portal for thousands of patients, doctors and growers. Through this company, he and his team have helped thousands of Canadians find legal, safe medication. His team also consulted, designed and submitted dozens of applications to the government under the MMPR, ACMPR and Cannabis Act. In 2011, Clelland co-founded Greenleaf Medical Clinic, which is now recognized as a training facility by the University of British Columbia and offers preceptorships to physicians, nurse practitioners and pharmacists. He also co-founded Folium Life Science in 2013, an approved Canadian Licensed Producer. His roles in these organizations have included Chief Operating Officer, head of security, alternate master grower and alternate responsible person in charge.

Josh Bromley, Senior Cultivation Strategist, is a second-generation farmer with over two decades of experience farming, breeding, cultivating and selecting unique cultivars for the medical community. He is an expert in plant science and possesses a comprehensive knowledge of cultivars and a mastery of medicinal implementation. Bromley has developed proprietary farming systems, as well as low cost/high output nutrient systems. Through thoughtful design and engineering, he has been able to consistently show improvements in crop yields, pathogen resiliency and quality.

Pac Roots Cannabis Corp. (PACR), closed Monday's trading session at $0.20, even for the day, on 5,000 volume with 1 trade. The average volume for the last 3 months is 13,048 and the stock's 52-week low/high is $0.11/$0.72.

Recent News

• CNS Pharmaceuticals (NASDAQ: CNSP) Announces Completion of Drug Manufacturing for Brain Cancer Trial
• Pac Roots Cannabis Corp. (CSE: PACR) Prioritizes Quality Through 'The Future of Genetics' Approach
• 420 with CNW - DEA Seeks Contractor with Capacity to Burn Tons of Cannabis Daily

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) was featured today in a publication from BioMedWire, examining how, for many living with heart and kidney diseases, taking care of their health includes managing their diets to suit medical recommendations that restrict the consumption of some nutrients. While this might be easy for some, a majority find it hard to follow these recommendations without tracking their nutrition through the day.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Monday's trading session at $1.68, off by 0.095147%, on 8,444 volume with 90 trades. The average volume for the last 3 months is 89,951 and the stock's 52-week low/high is $1.25820004/$5.68989992.

Recent News

• CNS Pharmaceuticals (NASDAQ: CNSP) Announces Completion of Drug Manufacturing for Brain Cancer Trial
• Researcher Develops App to Help Kidney, Heart Disease Patients Manage Diets
• CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Completion of Drug for Clinical Trials

AzurRx BioPharma Inc. (NASDAQ: AZRX)

The QualityStocks Daily Newsletter would like to spotlight AzurRx BioPharma Inc. (AZRX).

AzurRx BioPharma Inc. (NASDAQ: AZRX) was featured today in a publication from BioMedWire, examining how a group of researchers associated with various institutions in China has discovered a gut microbe deficiency in children who develop ASD (autism spectrum disorder). This is a developmental disability characterized by stereotyped and repetitive behavior and impaired social communication. In the research, which was published in the “Science Advances” journal, the team of researchers describes their study of gut microbes in autism spectrum disorder children and discusses their findings.

AzurRx BioPharma Inc. (AZRX) is a clinical-stage biopharmaceutical company focused on developing treatments for gastrointestinal diseases using recombinant proteins.

The company’s lead drug candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients suffering from cystic fibrosis and chronic pancreatitis.

AzurRx has already completed two Phase 2 clinical trials for MS1819 and is currently pursuing approval through parallel monotherapy and combination therapy pathways.

The company was founded in 2014 and is headquartered in New York City, with scientific operations in Langlade, France, and clinical operations in Hayward, California.

MS1819 Clinical Trials

The two current ongoing clinical trials for MS1819 in cystic fibrosis (CF) are the Phase 2b Option 2 monotherapy trial and the Phase 2 combination therapy trial, using MS1819 together with porcine pancreatic enzyme replacement therapy (PERT), the current standard of care. Pending the Phase 2b trial outcome, the company intends to initiate a Phase 3 trial in cystic fibrosis.

• Phase 2b CF Option 2 Trial – The study was initiated in Q3 2020, using MS1819 doses in enteric capsule form (2240mg and 4480mg). Topline data for the trial is anticipated in Q1 2021.
• Phase 2 CF Combination Trial – The study was initiated in Q4 2019, using daily dose levels of PERT in combination with MS1819 dosages (700mg, 1120mg and 2240mg). Topline data is anticipated in Q2 2021.

These trials are currently addressing the treatment of EPI in patients with cystic fibrosis and chronic pancreatitis – an established global market with an estimated value in excess of $2 billion that has been growing at a CAGR greater than 20% over the past five years.

Results from AzurRx’s Phase 2b Option 2 trial of MS1819 in cystic fibrosis patients demonstrate that the non-porcine MS1819 lipase is well-tolerated by patients, with no significant safety signals observed at the 2240mg daily dose level.

“[W]e have evaluated four different enteric capsules and identified the best suitable formulation for MS1819 that provides gastroprotection of enzyme content and delayed release into the duodenum,” James Sapirstein, President & CEO of AzurRx, stated in a September 2020 news release (https://ibn.fm/27t4W). “Our clinical program continues to advance, and we are determined to develop MS1819 as a safer alternative to porcine pancreatic enzyme replacement therapy, significantly reducing the pill burden of cystic fibrosis patients.”

Financial Highlights

As of July 2020, AzurRx had raised gross cash capital of $22.1 million, including $15.2 million from Series B convertible preferred stock and warrants in July 2020 and $6.9 million from convertible promissory notes and warrants in December 2019 and January 2020. Notably, AzurRx solidified its financial position and created an effectively debt-free balance sheet by exchanging substantially all of its outstanding convertible notes into the Series B convertible preferred stock financing.

The company secured an additional $2.5 million in French Research Tax Credits, received in 2020, for the years 2017-2019 (https://ibn.fm/Qxk7O).

In a letter to shareholder, Sapirstein noted that ensuring the company maintains sufficient capital to support its business operations has been a key focus. He further stated that the company is in “a financially secure position” to complete its two Phase 2 MS1819 clinical trial programs and to begin preparations in 2021 for a pivotal Phase 3 study.

The company has no current plans to access additional financing, as it believes it has enough cash to fund existing operational and clinical objectives through Q3 2021.

Management Team

James Sapirstein is the President and CEO of AzurRx BioPharma. He was previously the CEO and a board member for ContraVir Pharmaceuticals Inc., which is now known as Hepion Pharmaceuticals Inc. (NASDAQ: HEPA). Mr. Sapirstein has almost 36 years of experience in the pharmaceutical industry, with expertise in drug development and commercialization. He currently serves on the Emerging Companies and Health Section boards of the BIO (Biotechnology Innovation Organization) and is Chairman Emeritus of BioNJ. He earned his Bachelor’s degree in Pharmacy from Rutgers University and has an MBA in management from Fairleigh Dickinson University.

Daniel Schneiderman is the Chief Financial Officer of AzurRx. He previously served as the CFO of Biophytis SA and its U.S. subsidiary, Biophytis, Inc., clinical-stage biotechnology companies focused on the development of pharmaceutical candidates for age-related diseases. He was appointed to the AzurRx position in January 2020, bringing to the team over 18 years of experience in capital markets and finance operations. Mr. Schneiderman holds a degree in economics from Tulane University.

James Pennington, M.D., is the Chief Medical Officer of AzurRx. Before joining the team, he was the Chief Medical Officer and Senior Clinical Fellow for 11 years at Anthera Pharmaceuticals. Before becoming a part of the biotech industry, Dr. Pennington was on the Medical Faculty of Harvard Medical School for 10 years. He received his medical degree from Oregon Health & Science University.

Martin Krusin is the Senior Vice President for Corporate Development at AzurRx. He has 20 years of experience in business development, strategic marketing, financing and operations in the health care, financial services and consulting sectors. Before joining AzurRx, he was the VP for Business Development at FluoroPharma Medical Inc. Mr. Krusin received his MBA from Columbia Business School in finance and marketing, an MPhil. in political economy from Oxford University and a BA in international relations from Swarthmore College.

Dinesh Srinivasan, Ph.D., is the Vice President for Translational Research at AzurRx. He has over 15 years of experience leading drug discovery and development in the pharmaceutical industry. He began his career as a post-doctorate fellow at Roche Palo Alto. Dr. Srinivasan received his MSc in Biotechnology from the University of Mumbai, India, and a Ph.D. in Pharmacology and Toxicology from the University of Arizona – Tucson.

Ted Stover is the Product Development Director at AzurRx. He joined the company in 2020 to oversee CMC and Project Management. Before joining AzurRx, he spent 20 years focused on manufacturing operations and analytical method development for all stages of pharmaceutical drug development. Mr. Stover earned his MBA from the University of Florida.

AzurRx BioPharma Inc. (AZRX), closed Monday's trading session at $0.7199, off by 0.976616%, on 138,622 volume with 211 trades. The average volume for the last 3 months is 348,181 and the stock's 52-week low/high is $0.370867997/$1.93830001.

Recent News

• Findings Suggest Link Between Deficiencies in Gut Microbes, Autism Spectrum Disorder
• AzurRx BioPharma Inc. (NASDAQ: AZRX) Talks Porcine Usage, Producing Synthetic Alternative
• AzurRx BioPharma Inc. (NASDAQ: AZRX) Secures Financing to Fund Phase 2 Clinical Trials and Phase 3 Preparations

VistaGen Therapeutics Inc. (NASDAQ: VTGN)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics Inc. (NASDAQ: VTGN).

Noting that 17.3 million adults in the United States have had at least one major depressive episode and some 264 million people around the world suffer from depression, VistaGen Therapeutics (NASDAQ: VTGN) is committed to finding effective treatments for depression that reach beyond the current standard of care, which includes oral antidepressants and oral atypical antipsychotics. The company has released data from a second preclinical study of its oral investigational drug, AV-101, in combination with probenecid. The results, which complement findings from a prior preclinical study, indicate that AV-101, when combined with probenecid, substantially increased the brain concentration of its active metabolite, 7-Cl-KYNA, a potent and selective full antagonist of the N-methyl-D-aspartate receptor (NMDAr) glycine co-agonist site. The combination of drugs may therefore reduce rather than block NMDAr signaling—an effect which could carry significant therapeutic potential.

VistaGen Therapeutics Inc. (NASDAQ: VTGN) is a biopharmaceutical company committed to developing and commercializing a new generation of medications that go beyond the standard of care for anxiety, depression and other central nervous system (CNS) disorders.

The company is headquartered in South San Francisco, California, the “Birthplace of Biotechnology,” among the largest cluster of biotechnology companies in the world.

New Generation Medications

VistaGen currently has three innovative CNS drug candidates in its pipeline: PH94B, PH10 and AV-101. With a differentiated mechanism of action and an exceptional safety profile in all clinical studies to date, each of VistaGen’s three drug candidates offers significant commercialization potential in multiple large CNS markets.

PH94B

Fast-acting (10-15 minutes), non-systemic and non-sedating in Phase 2 clinical studies, PH94B is a first-in-class neuroactive nasal spray that, administered in microgram doses, binds to chemosensory receptors in the nasal passage that trigger neural circuits responsible for suppressing fear and anxiety caused by stressful social or performance situations.

PH94B is currently being developed as an acute treatment of anxiety in adults with Social Anxiety Disorder (SAD). In December 2019, PH94B became the first drug candidate to be granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for development of a treatment for SAD, positioning it to potentially become the first FDA-approved fast-acting acute treatment for adults with the anxiety disorder, if planned Phase 3 studies are successful.

A successful Phase 2 program has been completed, and, after achieving consensus with the FDA in mid-2020 that the design of its Phase 3 studies of PH94B in SAD may mirror the design of the highly statistically significant (p=0.002) Phase 2 public speaking study of PH94B in SAD, the company’s preparations for pivotal Phase 3 clinical development of PH94B are underway.

To support Phase 3 development and commercialization of PH94B for anxiety disorders in large anxiety disorder markets in Asia, VistaGen recently entered into a strategic licensing and collaboration agreement with EverInsight Therapeutics, a company formed and currently funded by a large global venture capital firm, CBC Group. The company received a $5 million non-dilutive upfront license payment from EverInsight in August 2020. If Phase 3 development is successful, VistaGen is eligible to receive additional development and commercial milestone payments of up to $172 million, plus tiered royalties on sales of PH94B in Greater China, South Korea and Southeast Asia. VistaGen retains exclusive rights to develop and commercialize PH94B in all other markets.

VistaGen is also assessing potential Phase 2A clinical development opportunities to evaluate PH94B in a range of other anxiety disorders, including:

• Adjustment Disorder with Anxiety
• Generalized Anxiety Disorder
• Postpartum Anxiety
• Perioperative Anxiety
• Panic Disorder
• PTSD

PH10

PH10 is an investigational fast-acting synthetic neuroactive nasal spray with therapeutic potential in a wide range of neuropsychiatric indications involving depression and suicidal ideation. VistaGen is initially developing PH10 as a potential fast-acting, non-sedating, non-addictive new generation treatment of major depressive disorder (MDD).

Upon self-administration, a microgram-level dose of PH10 sprayed into the nose binds to nasal chemosensory receptors that, in turn, activate neural circuits in the brain that lead to rapid-onset antidepressant effects, without side effects, systemic exposure or safety concerns that may be caused by FDA-approved drug treatments for MDD, including oral antidepressants and intranasal esketamine.

In a published exploratory Phase 2A MDD study, PH10 demonstrated rapid-onset and sustained antidepressant effects without the serious psychological side effects and safety concerns of ketamine-based therapy.

Following successfully completed Phase 2A development of PH10 for MDD, the company is currently preparing for a Phase 2B program in MDD.

VistaGen is also assessing the potential for Phase 2A clinical development of PH10 in a range of other depression-related indications, including:

• Postpartum Depression
• Treatment-resistant Depression
• Suicidal Ideation

AV-101

Part of a class of new generation investigational medicine in neurology and neuropsychiatry known as N-methyl-D-aspartate receptor (NMDAR) modulators, AV-101 is an oral prodrug of 7-chloro-kynurenic acid (7-Cl-KYNA), a potent and selective NMDAR glycine site antagonist. This drug candidate has the potential to serve as an innovative treatment for MDD and multiple neurological indications where current therapies are unsatisfactory.

VistaGen is currently evaluating AV-101, in combination with FDA-approved probenecid, in a range of neuropsychiatric and neurological indications, with both MDD and Neuropathic Pain already granted Fast Track designation by the FDA. The company is assessing the combination for a potential Phase 1B study to support a potential Phase 2A program in one or more of the following indications:

• Major Depressive Disorder
• Neuropathic Pain
• Levodopa-induced dyskinesia associated with Parkinson’s disease therapy
• Epilepsy
• Suicidal Ideation

CNS Therapeutics Market Outlook

The global CNS therapeutics market is estimated to reach $130 billion by 2025. The market was valued at approximately $82.3 billion in 2017 and is anticipated to grow at a healthy CAGR of more than 5.93% from 2018 to 2025. Even before the onset of the anxiety- and depression-provoking stressors from the COVID-19 pandemic, this growth was expected to be driven by a rise in mental illnesses and increased awareness of psychiatric disorders (https://nnw.fm/K2m0s) – all likely to be amplified by the diverse impacts of the pandemic.

The two most common mental health conditions – anxiety and depression – cost the global economy an estimated $1 trillion each year. The impact of these conditions is particularly devastating among the young. Industry data suggest that approximately 20% of the world’s children and teens are affected by mental health conditions, and suicide is the leading cause of death among 15- to 29-year-olds (https://nnw.fm/oftNb).

VistaGen’s mission is to help address the unmet needs of patients suffering from CNS disorders whose current treatments are either inadequate or generate debilitating side effects and serious safety concerns, including risk of abuse and death.

“Now more than ever, the new generation anti-anxiety and antidepressant medications we are developing at VistaGen – PH94B, PH10 and AV-101 – are relevant, necessary and demand the highly-focused and passionate efforts of our team and partners, with the support of our stockholders, to advance them to patients whose lives are disrupted by anxiety and depression disorders,” VistaGen CEO and Director Shawn K. Singh said in his closing remarks at the company’s 2020 Annual Meeting of stockholders.

Management Team

Shawn K. Singh, J.D. is the Chief Executive Officer and a Director of VistaGen. He has served on the company’s board of directors since 2000. He has nearly 30 years of experience serving in numerous senior management roles across multiple industries, including private and public biotechnology, pharmaceuticals, medical devices, venture capital, contract research and development, and law. Singh has a B.A. with honors from the University of California – Berkley. He has a J.D. degree from the University of Maryland Carey School of Law. He is also a member of the State Bar of California.

H. Ralph Snodgrass, Ph.D., is the Founder, Chief Scientific Officer and Director of the company. Snodgrass has more than 20 years of experience in the biotechnology field as a senior manager. He is recognized as an expert in stem cell biology, with over 28 years of experience using stem cells as biological research tools to promote development and drug discovery. He received a Ph.D. in immunology from the University of Pennsylvania. Snodgrass has published over 50 scientific papers with more than 17 patents and a number of patent applications.

Mark A. Smith, M.D., Ph.D., is VistaGen’s Chief Medical Officer He has over 20 years of pharmaceutical industry experience, primarily with CNS drug development. Smith has been a successful leader in the discovery and development of approximately 20 investigational new drugs. He has been a part of numerous CNS-related clinical trials. Smith received a bachelor’s and Master of Science from Yale University and a Doctor of Medicine and Doctor of Philosophy in Physiology and Pharmacology from the University of California – San Diego. He completed his residency in the psychiatry department at Duke University Medical Center.

Jerrold D. Dotson, CPA, is the Vice President, Chief Financial Officer and Secretary of VistaGen. He has over 25 years of experience in senior management positions in finance and administration at both public and private companies. Dotson is a licensed CPA in California and received his B.S. degree (Cum Laude) in business administration with a concentration in accounting from Abilene Christian College.

Mark A. McPartland is the company’s Vice President of Corporate Development and Investor Relations. He has over 20 years of experience in senior management roles in corporate development and investor relations at both public and private companies. McPartland received his Bachelor’s in business administration and marketing from Coastal Carolina University.

VistaGen Therapeutics Inc. (NASDAQ: VTGN), closed Monday's trading session at $0.6701, off by 6.3321%, on 1,007,403 volume with 1,933 trades. The average volume for the last 3 months is 1,653,454 and the stock's 52-week low/high is $0.294299989/$1.30999994.

Recent News

• VistaGen Therapeutics Inc. (NASDAQ: VTGN) Preclinical Study Data Show Drug Combo's Innovative Potential in Fight Against Major Depressive Disorder
• VistaGen Therapeutics (NASDAQ: VTGN) Featured in BioWorld Article
• InvestorBrandNetwork (IBN) Announces Latest Episode of Stock2Me Podcast Featuring VistaGen Therapeutics Inc. CEO Shawn Singh

Sanwire Corp. (SNWR)

The QualityStocks Daily Newsletter would like to spotlight Sanwire Corp. (SNWR).

Sanwire (OTC: SNWR), dedicated to employing digital technologies to provide a wide range of solutions for independent artists, stands to benefit from growing demand in the music industry. According to a report by MIDiA Research, digital technology and social media tools provide independent artists with powerful capabilities to create content and engage with fans during COVID-19 (https://ibn.fm/UH0z1). To view the full article, visit https://ibn.fm/ZmmD9

Sanwire Corp. (SNWR) is a diversified company currently focused on technologies for the music industry. The company specializes in locating unique opportunities in fragmented markets and implementing its aggregated technologies to consolidate distinct services into unified platforms of delivery. Sanwire is currently focusing these efforts on advanced entertainment technologies.

Founded in 1997 and based out of Las Vegas, Nevada, Sanwire has operated and sold several subsidiaries as it has worked in various industry segments, including Sanwire Software Inc., Bullmoose Mines Ltd. and Squeeze Report Inc. Currently, there are two new holdings that were added to the company’s portfolio through two recent acquisitions, including Intercept Music Inc. in March 2020 and the Art is War Record Label in June 2020.

Intercept Music Inc. – Artist-Focused Services

Intercept Music Inc. is an entertainment technology company offering a unique suite of artist-focused services that are specifically designed to meet the needs of recording artists. Intercept’s proprietary online platform is dedicated to helping millions of global independent artists effectively promote their music and distribute it worldwide to hundreds of digital stores and every major streaming platform, including Spotify, Apple Music, Amazon Music, Pandora and Google Music.

With Intercept Music, recording artists have all the tools needed to market, promote and sell their music online and through social media. Comprehensive reporting allows artists to track the fan response to their releases, all the way down to individual music tracks.

There are three foundations of Intercept Music’s product offering:

• Its music distribution platform that is well augmented via the company’s partnership with InGrooves, a wholly owned subsidiary of Universal Music, which is arguably one of the largest music companies in the world.
• Its social media system, which is tailored to work the way artists use social media to promote their music and engage with their fans. The scheduling system integrates artists’ profiles across multiple social networking sites (Facebook, Twitter, Instagram and YouTube) to facilitate new audience sampling, fan development and the ability for music to be previewed and purchased.
• The third is represented by the team of developers that brings a unique combination of deep technical expertise (in products like Skype), a team of well-accomplished executives and what the company calls Brand Ambassadors – senior reps from multiple genres who have helped artists earn over 100 Grammys.

Intercept Music is the confluence of technology and this music expertise.

The company currently markets three plans to its clients, with each offering different distribution and royalty options, as well as various marketing and reporting options. The plans are described below:

• Intercept Distro is a basic plan for self-service music distribution with royalty collection. Artists keep 100% of the royalties while receiving unlimited releases and full analytics with reporting.
• Intercept Artist includes all of the benefits of the basic Distro plan with added emphasis on social marketing and distribution for emerging artists. With this plan, artists receive scheduled and ad-hoc posting, social media reporting, reusable content libraries and access to other valuable features.
• Intercept PLUS is available by invite only and is for established artists looking for a complete suite of marketing, distribution and monetization services. The PLUS plan includes everything available through the Distro and Artist plans, as well as offering a dedicated service representative, a branded online store, on-demand merchandise, additional marketing, YouTube monetization and other pro features.

Intercept PLUS is the flagship plan. Artists of this caliber often do $3-$10k/month in merchandise sales alone, at 50%+ profit. Intercept is responsible for marketing to the fan base through its social media system and shares in the profits generated. The stores are managed by intercept so both top-line revenues and bottom-line profits flow through Intercept.

Intercept Music has partnered with Ingrooves Music Group, the largest online music distribution company in the world, for worldwide distribution to streaming services and leading stores. Completing more than 50 billion transactions weekly across over 150 countries, Ingrooves supplies music to leading streaming music platforms and lists some of the world’s largest and most reputable music labels among its clients. The partnership allows Intercept Music and its clients to reach a much wider audience and start earning revenue as soon as possible by leveraging Ingrooves’ quality control systems and direct relationships with leading music streaming services.

Physical Distribution Options for Intercept Music Clients

In a press release on June 25, 2020, Intercept Music announced that it would be offering artists physical distribution through major retailers such as Amazon, FYE and Walmart (http://nnw.fm/NSrbE). The physical distribution will consist of CDs and vinyl and will serve as a supplement to the online streaming platform access provided by the company to represented artists.

“In the current climate, artists can’t play shows or otherwise engage in public at all, so they’re focusing on all other opportunities to bring in revenue,” Intercept Music President Tod Turner stated in a news release. “Our only priority is to help artists monetize music in every way, and with physical distribution added to the mix, we’re leaving no stone unturned in helping artists to earn money from their creative output.”

Creation of Preferred Stock

On June 29, 2020, Sanwire CEO Christopher Whitcomb announced that the company would be filing certificates of designation with the Nevada Secretary of State for its Series A, B and C preferred stock (http://nnw.fm/svrQt).

Speaking about this designation in a news release, Whitcomb stated, “Our paramount goal is to maintain a balanced approach between future investments and shareholder value while minimizing shareholder dilution. The effective utilization of preferred stock ensures our company can grow with the least amount of shareholder dilution.”

Sanwire is leveraging a multi-dimensional strategy that includes additional acquisitions, attracting investors and enhancing the current balance sheet while minimizing dilution for shareholders. A primary goal of these efforts is to support Intercept’s ongoing operations.

Financial Highlights

For the fiscal quarter ended June 30, 2020, Sanwire announced significant revenue growth related to the acquisitions of Intercept Music and Art is War Records. Since acquiring Intercept Music in March and Art is War Records in June, Sanwire’s revenue has increased by approximately 300% (http://nnw.fm/j0S0j). Sanwire attributes the increase in revenue to Intercept Music’s customer acquisition and the release of its PLUS plan.

For the third quarter, revenue is expected to continue an upward climb, owing largely to physical distribution plans and a rising number of PLUS subscribers. The company’s acquisition of Art is War Records is also expected to fuel this growth.

Management

Christopher M. Whitcomb is the current CEO of Sanwire Corp. and Intercept Music Inc. He is a CPA in the state of California, holding bachelor’s degrees in accounting, corporate finance and business management with a focus on real estate. A seasoned executive, his business ventures are always strongly focused on the development and financing of companies.

Whitcomb worked alongside Ralph Tashjian at SMC Entertainment Inc. and Digital Music Universe. They are currently working together again following Sanwire’s acquisition of Intercept Music, which was founded by Tashjian.

Sanwire Corp. (SNWR), closed Monday's trading session at $0.0089, off by 9.6447%, on 96,602 volume with 6 trades. The average volume for the last 3 months is 644,356 and the stock's 52-week low/high is $0.003299999/$0.100000001.

Recent News

• Sanwire Corp. (SNWR) Empowers Artists to Innovate, Create During Pandemic
• Sanwire Corp. (SNWR) Enhances Entertainment Platform, Upgrades Technology Disrupting Music Industry Marketplace
• Sanwire Corp. (SNWR) to Thrive as Social Media Brings Lifeline to Artists in COVID-19 World

Wrap Technologies Inc. (NASDAQ: WRTC)

The QualityStocks Daily Newsletter would like to spotlight Wrap Technologies Inc. (NASDAQ: WRTC).

Wrap Technologies (NASDAQ: WRTC), an innovator of modern policing solutions, announced receipt of new and repeat domestic orders for BolaWrap(R) products and accessories. According to the update, the company has received numerous recent orders from domestic law enforcement agencies and expects to complete shipping next month. In addition, the company today announced the appointment of Jags Gill as its new director of international sales. Based out of London, Gill brings over 15 years of experience in senior sales management across global law enforcement and security sectors. To view the full press releases, visit http://ibn.fm/mDPUO and http://ibn.fm/AYjVW.

Wrap Technologies Inc. (NASDAQ: WRTC) is an innovator of modern policing solutions. The company’s BolaWrap® product is a patented, hand-held remote restraint device that discharges an eight-foot bola style Kevlar® tether to restrain an individual at a range of 10-25 feet. Developed by award-winning inventor Elwood Norris, the company’s chief technology officer, the small-but-powerful BolaWrap assists law enforcement in safely and effectively controlling encounters, especially those involving an individual experiencing a mental crisis.

Non-Lethal Weapons Market Potential

The BolaWrap Remote Restraint device is an innovative police solution, designed to provide law enforcement with a unique mobile and humane restraint option that does not inflict pain and enables subjects to be detained from a distance without the use of force.

In 2015, the 10 cities with the largest police departments in the United States paid out a cumulative $248.7 million in settlements and court judgements in police misconduct cases, marking a 48% increase from the $168.3 million in 2010 (http://nnw.fm/ri0L9). The majority of these cases have centered around the improper use of force by law enforcement when subjugating individuals, with 25% of all fatal shootings by law enforcement in the United States reportedly involving mentally ill individuals who are often incapable of comprehending officer commands (http://nnw.fm/YVm8P). Moreover, the use of alternate devices has failed to produce the desired outcomes, with the use of tasers by police resulting in over 1,080 fatalities since 2000 (http://nnw.fm/2Nb1A).

This, in turn, has led to a greater demand for humane tools which are not reliant on pain compliance to subdue subjects. Since its IPO in December 2017, Wrap Technologies has enjoyed a spectacular rise in prominence. The company began field testing the BolaWrap product in July 2018, with the first international order received only a month later, in August 2018. By December 2018, the company had been uplisted to the Nasdaq Capital Market with over 1,000 shareholders – a significant increase from the 50 shareholders who had participated in the IPO just 12 months prior. Recently, the company has sought to increase its commerciality and product monetization, appointing Tom Smith, the founder of TASER International (now Axon, NASDAQ: AAXN), as its president in March 2019.

At present, over 140 police departments throughout the United States are actively carrying the BolaWrap, while over 1,700 police departments across the nation have reached out to the company to request BolaWrap demonstrations, training and quotes. BolaWrap has also been successfully marketed internationally and has been shipped to 19 countries thus far.

As of today, Wrap Technologies has built a network of 11 distributors across 45 states in the United States who are actively marketing the product to the over 900,000 active police officers in the country. In addition, the company now has a network of 15 international distributors based in 26 countries – with over 600 international requests received thus far for product demonstrations, training and quotes.

As a result and following the opening of its new 11,000-square-foot manufacturing facility in Tempe, Arizona, in October 2019, Wrap Technologies announced a 352% year-on-year increase in revenues for 3Q2019 – a testament to the growing popularity of its mobile restraint device.

The company expects its growth to continue as adoption rates of the BolaWrap product increase throughout the United States and globally. According to a study by Stratistics MRC, the addressable global market for non-lethal weapons accounted for $6.32 billion in 2016 and is set to rise to $11.85 billion by 2023.

Product Received to Positive Acclaim

• “An innovation that is changing the world of policing.” – Chief Luther Reynolds, Charleston Police Department
• “Anytime you can have a more humane response to someone in crisis, it’s not only good for the department, it’s good for society.” – Redditt Hudson, Regional Field Director of the NAACP (http://nnw.fm/1STXm)
• “This is going to save lives.” – Chief Ed Hudak, Coral Gables Police Department
• “I see this as one of the great tools if you encounter someone with a mental health crisis.” – Chief Steven Casstevens, Buffalo Grove Police Department

Recently completed $12.4 million financing round

Wrap Technologies announced that it had successfully completed its capital raising round on June 4, 2020, raising $12.4 million through a primary share placement priced at $6.00/share. The net proceeds will be use to further scale engineering, fund product development and provide working capital to meet worldwide demand for BolaWrap products and accessories (http://nnw.fm/byLV7). The company also announced that its founder, Elwood Norris, had chosen to exercise 100,000 outstanding warrants to contribute $500,000 to the capital raising efforts. Following the financing round, Wrap Technologies reported over $30 million in cash on hand.

Management Team

Elwood G. “Woody” Norris, Founder and Chief Technology Officer
Elwood G. “Woody” Norris is an award-winning American inventor and serial entrepreneur and currently serves as chief technology officer for Wrap Technologies Inc. Norris founded and served as a director and president of Parametric Sound Corporation (now Turtle Beach Corporation (NASDAQ:HEAR)) and also served as chief scientist at Turtle Beach. Norris previously founded LRAD Corporation (NASDAQ: LRAD) and, prior to retiring in 2010, was chairman of LRAD Corporation’s board of directors, serving as a technical advisor and product spokesperson. Norris has authored more than 80 U.S. patents, primarily in the fields of electrical and acoustical engineering, and has been a frequent speaker on innovation to corporations and government organizations. He is the inventor of Wrap Technologies’ patented and patent pending BolaWrap® technology.

Scot Cohen, Executive Chairman
Scot Cohen has more than 20 years of experience in institutional asset management, wealth management, and capital markets. Cohen founded and served as principal of the Iroquois Capital Opportunity Fund, a closed-end private equity fund which focused on investments in North American oil and gas. Cohen also co-founded Iroquois Capital, a New York-based hedge fund that managed approximately $300 million across its family of funds. Prior to Iroquois Capital, Cohen founded a merchant bank which actively participated in structured investments in public companies. Cohen is currently active on a number of public and private company boards and is involved with various charitable ventures.

David Norris, Chief Executive Officer
David Norris is an experienced executive who joined Wrap Technologies full-time in January 2018. From April 2014 to December 2017, he served in various executive roles, including president, at privately held loanDepot LLC as it rapidly expanded into the fifth largest mortgage lender in the U.S. loanDepot had 6,000 employees and generated $1 billion in revenue in 2017. Norris also served as CEO of Greenlight Financial, and president of LendingTree Loans. Norris’ career also includes executive and management roles at Toshiba America Information Systems and Qualcomm Personal. Earlier in his career, Norris served as a probation officer in San Diego for five years.

Tom Smith, President
Tom Smith co-founded TASER International (now Axon Enterprise Inc. (NASDAQ: AAXN)) (“TASER”) in 1993 and served as president of TASER until October 2006. He served as chairman of the board of directors of TASER from October 2006 until he retired to pursue entrepreneurial activities in February 2012. Amongst his most significant roles and responsibilities at TASER, Smith managed domestic and international sales, significantly expanding the sale and distribution of TASER’s products, including sales to more than 17,200 federal, state and local law enforcement agencies in over 100 countries. In 2012, he founded Achilles Technology Solutions LLC, which, through subsidiary ATS Armor, developed a line of ballistic solutions for law enforcement and military applications. Smith holds a B.S. in ecology and evolutionary biology from the University of Arizona and an M.B.A. from Northern Arizona University.

Jim Barnes, Chief Financial Officer
Jim Barnes has served as president of Sunrise Capital Inc., a private venture capital and financial and regulatory consulting firm, since 1984. Barnes was chief financial officer of Parametric Sound Corporation (now Turtle Beach Corporation), and also served as vice president administration at Turtle Beach Corporation. Since 1999, Barnes has been manager of Syzygy Licensing LLC, a private technology invention and licensing company he owns with Elwood Norris. Barnes previously practiced as a certified public accountant and management consultant with Ernst & Ernst and Touche Ross & Co., and as a principal in J. McDonald & Co. Ltd. in Phoenix, Arizona.

Wrap Technologies Inc. (NASDAQ: WRTC), closed Monday's trading session at $5.61, up 8.5106%, on 773,778 volume with 3,976 trades. The average volume for the last 3 months is 833,946 and the stock's 52-week low/high is $3.06999993/$14.3999996.

Recent News

• Wrap Technologies Inc. (NASDAQ: WRTC) Secures New, Repeat BolaWrap(R) Orders, Appoints New Director of International Sales
• Wrap Technologies Announces Tom Smith as Interim CEO
• Wrap Technologies Reports Third Quarter 2020 Results

Jupiter Wellness Inc. (NASDAQ: JUPW)

The QualityStocks Daily Newsletter would like to spotlight Jupiter Wellness Inc. (NASDAQ: JUPW).

Jupiter Wellness (NASDAQ: JUPW) is a functional wellness and natural health products company. It leverages a proprietary line of offerings formulated to provide the therapeutic and medical benefits of cannabidiol (“CBD”). Jupiter Wellness is dedicated to advancing research into CBD for treatment and relief of a range of ailments, including ultraviolet exposure, psoriasis, eczema, skin aging and other conditions. Formed in 2018 and headquartered in Jupiter, Florida, Jupiter’s award-winning portfolio contains seven unique CBD brands targeting specific niches of the larger CBD space. Jupiter Wellness retails its full portfolio of brands and products on its ecommerce site at www.CBDCaring.com. For more information, visit the company’s website at www.JupiterWellnessInc.com.

Jupiter Wellness (NASDAQ: JUPW) is a functional wellness and natural health products company. Through its proprietary line of offerings leveraging the therapeutic and medical benefits of cannabidiol (CBD), the company is dedicated to advancing research into CBD for treatment and relief of a range of ailments, including ultraviolet exposure, psoriasis, eczema, skin aging and other conditions.

Jupiter Wellness was formed in 2018 and is headquartered in Jupiter, Florida.

An Award-Winning Brand Portfolio

Jupiter Wellness currently markets seven unique CBD brands targeted toward specific niches of the larger CBD space. These brands include:

• CaniSun – This line of products is dermatologist tested and recommended. Its high-performance, ultra-moisturizing formulas provide protection from UVA, UVB and IRA rays while defending skin against photo-aging and dehydration.
• fitCBD – This line is ideal for athletes of all levels seeking to incorporate CBD into their training regimens. fitCBD proudly incorporates natural, proven essential oils and cutting-edge CBD technology in a selection of vegan, natural and cruelty-free formulations.
• Wellness CBD – This brand includes products designed to provide immediate support through a proprietary combination of essential oils and industrial hemp-derived CBD.
• Black Belt CBD – This brand features products formulated to offer immediate relief for the most exhausted and stressed muscles. Menthol provides immediate cooling action, while a proprietary essential oil blend helps boost recovery time.
• Bella – This product line includes a wide selection of luxury skin and hair products designed to boost lift and shine by leveraging the antioxidant power of CBD.
• Felix & Ambrosia – This brand features premium CBD-infused foot cream formulated to provide immediate relief for long days in high heels and boots, as well as award-winning flavored lube available in five tantalizing flavors.
• Jack – This line of CBD-infused creams, serums and moisturizers is designed to meet all of the skincare needs of even the most rugged of adventurers.

Jupiter Wellness retails its full portfolio of brands and products on its ecommerce site, www.CBDCaring.com.

Share Offering

On October 13, 2020, Jupiter Wellness filed a preliminary prospectus with the U.S. Securities and Exchange Commission detailing plans to offer one million units consisting of one share of common stock and one warrant in a firm commitment initial public offering at an assumed price of $7.50 per unit (https://ibn.fm/jGmkc). Each warrant is immediately exercisable and entitles the holder to purchase one share of common stock at an exercise price of $8.50. Warrants will expire five years from the date of issuance.

In line with this proposed offering, the company has been approved to list its shares and warrants for trading on the Nasdaq Capital Market, subject to official notice of issuance, under ticker symbols ‘JUPW’ and ‘JUPWW’, respectively.

Management Team

Brian John is the CEO of Jupiter Wellness. For the past 20 years, he has been an investor and advisor to companies around the globe. He is the founder of a highly successful financial consulting firm specializing in assisting emerging growth companies and has worked with hundreds of companies in dozens of countries over the last 25 years. John also serves on the board of directors of The Learning Center at the Els Center of Excellence – a school for children with autism in Jupiter, Florida.

Richard Miller is the COO of Jupiter Wellness. Since 2000, Miller has managed a consulting firm that advises emerging growth companies. Over the last 20 years, he has provided strategic advice to hundreds of companies across diverse industries. He has assisted C-Level executives with expanding, financing and other challenges facing emerging companies. Miller co-founded Teeka Tan Suncare Products. Prior to the company’s sale, he was instrumental in the design and launch of a full line of boutique suncare products. He managed the deal from concept to sale. He is an advocate for school safety and local schools through his grass roots group, ‘My School Counts’.

Doug McKinnon is the CFO of Jupiter Wellness. His 35+ year professional career includes financial, advisory and operation experience across a broad spectrum of industry sectors, including oil and gas, technology, cannabis and communications. He has served in C-Level positions in both private and public sectors, including as chairman and CEO of an American-stock-exchange-traded company; as VP – Chief Administrative Officer of a $12-billion-market-cap Nasdaq-traded company; as CFO of several publicly-held U.S., Canadian and Australian companies; and as CEO/CFO of various other private enterprises.

Jupiter Wellness Inc. (NASDAQ: JUPW), closed Monday's trading session at $5.40, off by 10.00%, on 192,297 volume with 5,791 trades. The stock's 52-week low/high is $5.40000009/$6.90000009.

Recent News

• Jupiter Wellness Inc. (NASDAQ: JUPW) Advancing CBD Research to Bring Innovative Products to Underserved Markets
• CaniSun a subsidiary of Jupiter Wellness Inc. to Exhibiting at Surf Expo in Orlando, FL, January 8-10
• Jupiter Wellness Inc. Initiates Study to Investigate a Novel Cannabidiol Lotion for the Treatment of Atopic Dermatitis (Eczema)

Friendable Inc. (FDBL)

The QualityStocks Daily Newsletter would like to spotlight Friendable Inc. (FDBL).

Friendable Inc. (FDBL) is a mobile technology and marketing company focused on connecting and engaging users through its proprietary mobile and desktop applications. Launched July 24, 2020, the company’s flagship offering is designed to help artists engage with their fans around the world and earn revenue while doing so. The livestreaming platform supports artists at all levels, providing exclusive artist content ‘Channels’, LIVE event streaming, promotional support, fan subscriptions and custom merchandise designs, all of which serve as revenue streams for each artist.

With Fan Pass, artists can offer exclusive content channels to their fans, who can use their smartphones to gain access to their favorite artists, as well as an all-access pass to all artists on the platform. Additionally, the Fan Pass team will deploy social broadcasters to capture exclusive VIP experiences, interviews and behind-the-scenes content featuring their favorite artists – all available to fan subscribers on a free trial basis. Subscriptions are billed monthly at $3.99, or about the cost of downloading a couple of songs, and VIP experiences are available at a fraction of the cost of traditional face-to-face meetups.

Friendable Inc. was founded by Robert A. Rositano Jr. and Dean Rositano, two brothers with over 27 years of experience working together on technology-related ventures.

The Fan Pass Mobile & Desktop App

Friendable Inc. launched its Fan Pass platform as a solution for artists and their fans as the COVID-19 pandemic and the associated shutdown have continued to severely hamstring the entertainment industry as a whole. Through Fan Pass, the company aims to reach artists at all levels looking to alter their touring schedules to include ‘Virtual Touring’, new revenue sources and innovative fan engagement opportunities that are expected to become permanent fixtures of artists’ touring routines moving forward.

Fan Pass creates an ecosystem that embraces fans of all kinds, feeding diehard followers and developing lasting connections with more casual supporters. Through the app, qualified artists are provided with a custom designed, exclusive ’Fan Pass Channel’ where they can invite fans and social followers from anywhere around the world to join in chats and live events – allowing fans to experience all there is to see of an artist in one place. Artists earn revenue from monthly fan subscribers, merchandise sales, tickets sold for virtual streaming events and generally from all content views or impressions on their channels. All content views and sales of every kind are reported to each artist through their dashboards, including real-time payout and earnings information.

Fan Pass’ exclusive ‘All Access VIP’ option provides fans with access to content, such as:

• Live performances or online concerts
• Backstage meetups before, during or after events
• Livestreams of studio sessions
• Behind-the-scenes footage of music video and photo shoots
• Special interviews and one-on-one videos
• Streams highlighting the artists’ daily lives

The Fan Pass platform is extremely intuitive, bringing each artist through a streamlined onboarding process, including building out artist ‘Channels’, scheduling LIVE events and designing special edition merchandise to be offered solely through exclusive Fan Pass merchandise stores.

“With the global pandemic disrupting the entertainment industry in such a profound way, artists have had to look to digital distribution and live virtual performances in order to maintain any earning opportunities. Fan Pass and our team are determined to provide solutions and support to all artists, their fans and the industry in general. We are excited about the opportunity we have to shape the future of virtual entertainment, revenue generation and artist/fan engagement,” Robert A. Rositano Jr., CEO of Friendable Inc., stated in a news release.

Market Opportunity

Artists rely heavily on revenue streams that are not often seen by those without intimate industry knowledge. When it comes to traditional performances, the sale of VIP/backstage or meet & greet passes to boost revenue can often become the majority of the artist’s annual tour revenue. Data provided by one of the company’s original entertainment partners, The Kluger Agency (TKA), suggests that as much as 18-23% of artists’ annual tour revenue has historically been derived from these VIP experiences.

The World Economic Forum reports that, in 2020, the six-month-plus disappearance of live music concerts is estimated to have cost “the industry more than $10 billion in sponsorships,” and individual artists are feeling the loss the most. Fan Pass is helping to bridge this gap, providing more affordable virtual VIP experiences that can be offered simultaneously to fans around the world.

While it’s free for artists to join, Fan Pass leverages a monthly subscription model paid by fans to generate revenues. These revenues are shared with all channel artists. In exchange for its platform features, live streaming tools, bandwidth, processing and handling, Fan Pass earns platform fees on each separately ticketed event, as well as splits with each artist on subscriber fees and merchandise designed and sold on the platform.

The U.S. video streaming industry is expected to hit $7.08 billion in value in 2021, with an estimated 100 million internet users watching online video content every day, according to data from Livestream.com. The same report suggests that 45% of live video audiences would pay for exclusive, on-demand video from a favorite team, speaker or performer. Through Fan Pass, Friendable Inc. is uniquely positioned to capitalize on this opportunity.

Friendable App

The company’s second application, Friendable, is an all-inclusive platform where users can meet, chat and date. The app has exceeded 1.5 million total downloads, with over 900,000 historical registered users and more than 580,000 historical user profiles.

Friendable Inc.’s Next Phase of Growth

To facilitate its next phase of growth, Friendable Inc. is seeking an additional $1 million in equity investment, with a follow-on funding that meets or exceeds $5 million. The company intends to utilize its relationships to secure the lowest cost of capital available, as these funds will drive technology advancements, increase head count, fund marketing initiatives and secure additional celebrity talent aimed at bringing larger fan audiences to each released event. These initiatives will assist in building recurring monthly (fan) subscribers, effectively generating recurring monthly revenue for each artist, as well. The next phase of growth is expected to play a key role in accelerating the company’s download and conversion of data for subscription revenue and merchandise sales.

The company’s primary goal is to establish Fan Pass as a premier brand and mobile platform dedicated to connecting and engaging users around the world. In support of this goal, it has entered into a partnership with Brightcove targeting OTT platform expansion, including leaders such as iOS, Android, Apple TV, Android TV, Roku and WWW.

In the highly competitive video streaming market, Friendable Inc. has tapped into an unmet demand from today’s ever-present ‘omni-users’ for constant contact with celebrities and influencers. Via Fan Pass, the company offers investors an opportunity to gain a stake in an organization catering to this new breed of omni-users and their influencers.

The application’s potential is clearly illustrated by the interest it has generated in recent weeks. From September 4 to October 12, the Fan Pass platform added 246 new artists, accounting for a 410 percent increase in just six weeks.

“We are extremely encouraged by the ongoing swell of interest as the value of our Fan Pass platform continues to resonate in the artist community,” Friendable CEO Robert A. Rositano Jr. stated in a news release. “We believe the live streaming functionality, our full-circle offering and diverse revenue opportunities the platform offers will continue to drive exponential growth as management remains focused on building long-term shareholder value.”

Management Team

Robert A. Rositano Jr. is the co-founder and CEO of Friendable Inc. He oversees the daily management and operational duties of all areas of the business. He has over 20 years of experience as a serial entrepreneur, bringing in over $60 million in liquidity events for the companies he has created or managed. Before starting Friendable Inc. with his brother, Rositano was a founding member of the internet’s first IPO, Netcom Online Communications Inc. It was sold to ICG, then to EarthLink in 1995. He has been a co-founder of several successful ventures, including Simply Internet Inc., Nettaxi.com and America’s Biggest Inc., among others. He also authored one of the first web directories for MacMillan Publishers.

Dean Rositano is the co-founder and Chief Technology Officer of Friendable Inc. He handles the day-to-day operations and guides the technical direction of the company. He has over 15 years of executive management, financial management, high technology operations and internet architecture experience. Before co-founding Friendable Inc., Rositano co-founded several other companies, including Checkmate Mobile Inc. and Latitude Venture Partners LLC, among others.

Friendable Inc. (FDBL), closed Monday's trading session at $0.01875, up 10.2941%, on 2,107 volume with 6 trades. The average volume for the last 3 months is 219,146 and the stock's 52-week low/high is $0.01575/$0.524999976.

Recent News

• Friendable's Fan Pass Platform Records 128 New Artist Sign Ups Since Oct. 13, 2020, with Totals Now Surpassing 469 Artists Since its July 2020 Launch
• Friendable Inc. (FDBL) Fan Pass Live Platform Bridges Gap Between Artist Performances, Fan Experience
• Friendable Inc. (FDBL) to Bring Entertainment to Virtual Stage Through First Official Fan Pass Live Halloween Event